Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
65K in volume. Twice the daily average.
I'm not a chartist but I'd be curious to see what a chartist says about the recent activity. IMO I think it inches higher.
Volume is increasing
Average volume per yahoo is about 30K
Last 5 days
224K
127K
30K
10K
152K
Lots of trading today.
It was .59/.60 and 20K went off at .60
And now it's .58/.59 That's odd.
HFGB..$0.62..
I have been adding to my position in the low $0.50's each time it has traded there.. I sold some @$0.66 plus the first move up last month and another 20,000 this time @$0.5988.. I love the story but just how much is too much of a good thing.. My last sale seems that it might of been a bad trade but.. still long 63,128 at an Ave now of $0.6422.. No longer out of range and my Ave. has been brought down from almost $0.85...
From here I will continue to add on weakness as HFGB and CHHE are still my favorite stocks from China.. hank
Does anybody know the reason for the 477K share sell off on June 1st that decreased share price from over .90 to about today's price of .60?
I'm in at .62 and thinking of adding a bit more here along with opening a position in SRRY at .30
These 2 stocks will be my China investments.
Had to grow a hairy mole to get broker to engage this request:
09/23/2010 09:37:27 Bought 6000 HFGB @ 0.512 -3,077.00
At $0.63 hfgb is holding & digesting its gains of the past two weeks rather well.
Still the pps needs to rise another $0.14 just to get to B.V. & the current p/e ratio is still less than 3.
Volume has picked up in these last two weeks & if volume continues strong after this consolidation a return to previous highs of $1.40 by early next year would be my expectation.
But even then hfgb would be far below fair value for such a well run company growing very consistant & rapid organically & thru meassured acquisitions.
cleezdeez if there's any advice or opinion on SRRY you could share I'd appreciate it. The China market is new to me.
I've decided to take a position in HFGB. Now just have to get my entry point, buy it and hold.
With HFGB's earnings and guidance I'd pay 2.00 for it today. At .60 I'm very interested.
we must be following the same scent...love the numbers on this one too.
SRRY: nice entry opp today, not as dirt cheap as HFGB IMO, but a stable no-brainer of a business model that will grow at least in line with the rest of the SE Asia.
Spent a few hours trying to DD this one
Love the business and the numbers. Look like it's suffering from China syndrome. Lots of China stocks with small PE's and that bald-headed jerkoff on CNBC saying to sell China stocks.
I'll be buying some to tuck away. The value is too good to pass up here.
Also looking into SRRY at about .30 but that'll be another day as I'm tired from reading all I could find about HFGB
The great news coming from hfgb has been completely ignored by a market that has very little interest in Chinese stocks on U.S. exchanges.
HFGB does its business on international markets along with being the premiere supplier "rutin" & many other products in China.
They have a eye on becoming a full service pharm. company 3x its present size.
Thus the market is looking for stock dilution to cover those costs.
HFGB has plenty of growth left in its present nitche & GMP certication only increases the market range for HFGB products.
So with the pps depressed due to market conditions they really need not be in a hurry to fund that future growth since the present backlog should continue to grow as they add Japan & the U.S. & many other places to their growing customer list with GMP certification.
HFGB has everything going its way except the current pps & that should change big time when the market regains the realization that China will continue to lead the World in growth & stocks like hfgb are on the cutting edge of that growth curve.
Presently I see at least $0.21 eps with increasing margins & cashflow this year as being within reach in spite about 25% more shares & barring more dilution about $0.35 in 2011 with a B.V. north of a buck.
Currently around $0.55 hfgb in my opinion is one of the biggest bargains in the market & should command a p/e ratio of 10-15 once the market again takes a liking to the fastest growing stocks in the World.
And thats allowing for a normal China discount. imo
nice news...have this on radar....
HFGB.. $0.51... Reinspection Approval of GMP Certificate
Huifeng Bio-Pharmaceutical Technology Announces the Reinspection Approval of GMP Certificate
XIAN, China, Sept 23, 2010 /PRNewswire via COMTEX/ -- Huifeng Bio-Pharmaceutical
Technology, Inc. (HFGB) ("the Company"), specializing in developing and producing
botanical extracts and other raw materials for pharmaceuticals and food
additives, today announced the reinspection approval of Good Manufacturing
Practice ("GMP") certificate by the State Food and Drug Administration (SFDA) on
September 7, 2010. All pharmaceutical companies in China are required by SFDA to
gain GMP Certificate for the production of pharmaceuticals.
The implementation of Good Manufacturing Practice ("GMP") is an effective measure
for assuring the quality, safety, and effectiveness of pharmaceutical products.
Such GMP certificate is valid for five years. After the validity period has
transpired, a full inspection will be conducted by SFDA to check whether the drug
manufacturer still meets the GMP requirements. With the rapid development of
China's economy, GMP is a forced requirement for Chinese pharmaceutical plants
and has become more and more important for those Chinese pharmaceutical companies
that want to export their products to the world markets.
"GMP certificate is a rigorous process that we are delighted to have approval of
reinspection successfully," began Mr. Jing'an Wang, the Chief Executive Officer
of Huifeng Bio-Pharmaceutical. "The approval of GMP certificate has a significant
impact on our company's future success; this further proves the superior quality
standards of our products. This certification allows us to move forward to expand
not only our domestic market but also our oversea markets, such as in U.S.,
India, European countries, Japan and South America as GMP is required by their
government."
"With gaining GMP Certification, we would see great potential growth in our sales
in the following quarters," Mr. Wang continued.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic
of China, develops and produces plant extracts and pharmaceutical raw materials
for use in pharmaceutical, nutraceutical and food production. It is the leading
Chinese producer of rutin and related plant-derived chemicals in a class called
flavonoids, with medicinal and other beneficial properties. Founded in 2002,
Huifeng uses proprietary patented processes to extract rutin more efficiently
than traditional extraction techniques. The Company is diversifying its product
lines through internal development, acquisition and cooperation with scientific
research organizations. More information can be found on the Company's web site
at: http://www.hfgb.cn/
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of
the "safe-harbor" provisions of the Private Securities Litigation Reform Act of
1995. Such statements involve known and unknown risks, uncertainties and other
factors that could cause the actual results of the Company to differ materially
from the results expressed or implied by such statements, including changes from
anticipated levels of sales, future national or regional economic and competitive
conditions, changes in relationships with customers, access to capital,
difficulties in developing and marketing new products, marketing existing
products, customer acceptance of existing and new products, and other factors
disclosed in the Company's Annual Report on Form 10K for the year ended Dec. 31,
2009 and all of the Company's subsequent Quarterly Reports on Form 10Q,
especially in the "Risk Factors" sections of these reports. Accordingly, although
the Company believes that the expectations reflected in such forward-looking
statements are reasonable, there can be no assurance that such expectations will
prove to be correct. The Company has no obligation to update the forward-looking
information contained in this press release.
For more information, please contact:
Investor Relations:
NUWA GROUP
Mr. Kevin Fickle
Tel:+1-925-330-8315
Email: Kevin@capitalgc.com
Company Contact:
Huifeng Bio-Pharmaceutical Technology, Inc.
Ms. Bing He
Tel:+86-139-9195-4170
Email: bing@xahuifeng.com
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
HFGB.. $0.5492.. Cross post from GeoTeam®
http://geoinvesting.com/companies/hfgb_huifeng_bio_pharma_tech/research
Xian, China, September 14, 2010- Huifeng Bio-Pharmaceutical Technology, Inc. (OTCBB: HFGB)(“the Company”), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announced the approval of GMP Certificate by the SFDA on September 7, 2010, and the Certificate No. is Shaan L0407.
The approval of GMP Certificate has a great significance for the Company. GMP Certificate is required for pharmaceutical raw materials like rutin and troxerutin by SFDA. With this Certificate, the Company can sell their products to domestic finished medicines plants. GMP certificate is also required by some foreign countries such as South America, U.S., India, and Japan. Rutin and troxerutin are used for nutriceutical, pharmaceutical, cosmetics, and fuctional beverage as active pharmaceutical ingredients in these foreign countries. GMP Certificate is an important passport for the pharmaceutical companies, which indicate the company’s products have a solid quality guarantee. The approval of this Certificate will increase the domestic sales in the following quarters.
------------
Wednesday, September 8, 2010
Acquisition Activity
On September 2, 2010, Huifeng Bio-Pharmaceutical Technology, Inc., a Nevada corporation (the “Company”), through its wholly-owned subsidiary, Xi’an Huifeng Bio-Technic Inc.(“Xi’an Huifeng”), a company organized and operating under the laws of the Peoples' Republic of China ("PRC"), entered into an Acquisition Agreement with Shangqiu Kexin Rutin Processing Ltd. (“Kexin”), a company organized and operating under the laws of the PRC (the “Acquisition Agreement”).
Pursuant to the Acquisition Agreement, the Company agreed to purchase 90% of the equity of Kexin for $140,000 in cash and 2,300,000 restricted shares of the Company's common stock at a per share price of $0.70.
In addition, the Company, through its subsidiary Xi’an Huifeng, has agreed to loan Kexin $1,000,000, at a 10% annual interest rate, to help Kexin reach its projected annual net income of $650,000 for the next three years; provided, however, that should Kexin fail to achieve average projected annual net income of $650,000 in the next two years, the annual interest rate shall be adjusted to 20%.
GeoTeam® note:
Pre-transaction and using the current share count of 25,408,941, HFGB was on track to report EPS of $0.19 on its mid point net income guidance of $4.75 million. Applying the new share count of 27,708,941 and assuming that HFGB will realize about 33.0% of Kexin's net income contribution, we estimate that 2010 EPS will still come in at about $0.19. Overall, it appears that the transaction will be slightly accretive in 2011. We would have preferred that HFGB would have placed greater growth demands on Kexin. We have also asked HFGB to provide more color on how much of the $650,000 will hit its books for the remainder of 2010.
$0.5201-$0.1063 or 16.97% on increased volume of 87,499 shares traded.
Yesterday it was the likes of born uta ccme snbp that took huge drops.
Tuesday ckgt got creamed.
Other than a sneaky short raid on uta I have seen no reason for these huge unwarranted drops if one believes the financials for each of the above mentioned "Chinese" stocks.
How much longer these attacks on Chinese based U.S. stocks will continue is anyones guess but the p/e ratios are clearly out of wack with the fundamentals.
Does the market really believe that all Chinese stocks are frauds or that no possible growth can be coming from China.
I think their are some unbelievable values in Chinese stocks today & have put 50% of my cash into 10 China plays.
The about 40% cash I have left after selling born with luck near its highs I plan on keeping in reserve until the pps of these extremely undervalued stocks start heading in the direction of their true values.
As I do believe the trend is your friend even if the fundamentals look great.
Until the funds with the big dollars join us small guys we can't continue to fight the tape. imo
So I will stay with what I have unless the fundamentals are proven wrong. So far that has not been the case in any of my China plays although I am sure some China stocks maybe frauds just as many U.S. based U.S. stocks have also been.
It was posted yesterday
Pappy, thanks for bringing HFGB to my attention a while back. I have added to my position in the past week in this .55-.56 range and now consider this my best share price growth opportunity in my port.
HFGB was already the leading supplier of "rutin" in China & has been filling huge order increases for that product & "diosmin" from new & expanded contracts from Europe.
This acquisition is not only acretive to eps but adds needed manufactoring capacity at a time it is trying to fill its backlog.
Since cashflow & pps is not high enough presently to complete HFGB's mission of becoming a much bigger full pharm.
The company is doing a good job of getting the best results from the present situation.
Smart management is adapting to reasonable & affordable ways to grow the company.[notice the shares were not only accepted @$0.70 when the current pps was $0.55 but they are restricted from trading those shares for 1 year.]
Bob Stocks, would you mind posting this on China Growth Stocks board...I'n not premium member, but this is good news to share. TIA!
Acquisition news today for HFGB!
Terms of deal are for payment at $.70/share. Today, HFGB is trading at $.56 or a 25% discount to terms and to book value.
Deal will add $.03 to EPS bringing 2010 net income to around 5,750,000 or $.22.
Trading at 2010 PE of 2.54. Will post year over year EPS growth of 50% ($.15 to $.22)
HFGB.. $0.55...Acquisition
PRESS RELEASE: Huifeng Bio-Pharmaceutical Technology, Inc. Announces the Acquisition of Shangqiu Kexin Rutin Processing Ltd.
Dow Jones & Company, Inc. - Sep 09 at 08:31
Company Symbols: NASDAQ-OTCBB:HFGB
XI'AN, China, Sept. 9 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB) ("Huifeng" or the " Company"), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announces a definitive agreement under which Huifeng will acquire 90% of the equity ownership of Shangqiu Kexin Rutin Processing Ltd. ("Kexin"), a local leading Rutin manufacturer in Henan Province, at a price of $1.75 million. As a result of the acquisition, Kexin will be a wholly-owned subsidiary of Huifeng.
According to the Acquisition Agreement, the Company will acquire 90% of the equity ownership of Kexin by issuing 2,300,000 restricted shares of the Company's common stock at the basis of $0.7 per share and paying $140,000 in cash to Kexin. The average annual net income of Kexin is expected to be $650,000 in the following three years.
"We are proud to include Kexin as part of the Huifeng family. Kexin has a strong reputation for crude rutin and some high quality rutin series products that deliver value to pharmaceuticals plants and healthcare professionals around the world," said Jing'an Wang, the Chief Executive Officer of Huifeng Bio- Pharmaceutical Technology, Inc. "The experience and technology of Kexin are critical to the development of our markets."
Mr. Wang continued, "With the addition of Kexin's diverse rutin products, Huifeng will be able to offer a full range of rutin series products to our customers, which will definitely leverage Huifeng's brand recognition as the largest Rutin producer in China and a prominent generic pharmaceutical company in many other markets. We believe Kexin will contribute to our long-term success."
Huifeng expects to complete the transaction within one month.
About Shangqiu Kexin Rutin Processing Ltd.
Shangqiu Kexin Rutin Processing Ltd. is a local leading Rutin manufacturer, based in Shangqiu City, Henan Province. Kexin is engaging in developing, manufacturing and distributing rutin series products, such as crude rutin and some high quality rutin series products.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the company's web site at: http://www.hfgb.cn/ .
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors disclosed in the Company's Annual Report on Form 10K for the year ended Dec. 31, 2009 and all of the Company's subsequent Quarterly Reports on Form 10Q, especially in the "Risk Factors" sections of these reports. Accordingly, although the Company believes that the expectations reflected in such forward- looking statements are reasonable there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact:
Investor Relations:
NUWA GROUP, LLC.
Mr. Kevin Fickle
Tel: +1-925-330-8315
Email: Kevin@capitalgc.com
Company Contact:
Huifeng Bio-Pharmaceutical Technology, Inc.
Mr. Steven Tong, IR Director
Tel: +86-135-721-18351
Email: Steven@xahuifeng.com
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
/CONTACT: Investor Relations: NUWA GROUP, LLC., Mr. Kevin Fickle, +1-925- 330-8315, or Kevin@capitalgc.com; Company Contact: Huifeng Bio-Pharmaceutical Technology, Inc., Mr. Steven Tong, IR Director, +86-135-721-18351, or Steven@ xahuifeng.com
/Web site: http://www.hfgb.cn
love the acquisition today. I applaud management for a great move.
You can add $.03 to your EPS with today's announced acquisition.
Glad I bought more today at $.56!
This little guy is just getting started...will be fun to see him grow up to be a big boy.
Although I have HFGB eps @$0.225 for 2010 making the PE metric about even I think CKGT maybe about to win that metric comparison after todays pps drop.
I have seen one 2010 EPS projection of $0.51 & with the current pps hovering around $1.05 that makes 3 China stocks growing very fast but selling very cheap.
I haven't looked @ the book value for ltus lately but ckgt & hfgb are both selling well below B.V. of $1.73 & $0.77.
As to a revenue growth metric a must fore runner for substainable growth I believe HFGB & CKGT have a huge lead over LTUS although LTUS seems to be regaining on that front since I sold it a while back.
All 3 stocks deserve to be much higher but then we already knew that.
LTUS by a nose...on 2010 PE metric.
2010 PE:
HFGB, 2.67 ($.21 EPS)
LTUS, 2.47 ($.38 EPS)
Is there a more undervalue stock than HFGB at the present time.
A conservative management gave 2010 guidance of a revenue range from $20-25M.
They are on pace to have revenue near $30M.
Net income guidance of a range from $4.5-5M.
They are on pace to have net income near $6M
With 25% more shares outstanding this year they already have eps of $0.10 vs $0.02 last year.
Look at the stocks history about 2/3rd of revenue & most profits are registered in the 2nd half which is harvest & squeezing season.
Last years 1st half revenue of $4,417,420 became full year revenue of $13.7M with net income of $3M or $0.15 eps.
In this years 1st half HFGB had revenue of $10,850,838 extending the obviously good revenue gains of the traditionally slow 1st half its easy to see HFGB with 2010 revenue closer to $30M than their guidance for $20-25M.
With more revenue has come increased margins so I think net income closer to $6M than the $4.5-5M guidance HFGB gave is likely.
Analyst numbers I have seen have HFGB's eps @$0.20 in 2010.
I think even taking into consideration the increase in shares for 2010 that HFGB should beat that $0.20 eps projection by 10-15% giving HFGB about 50% eps growth over 2009.
Most of this gain will be thru internal growth as no planned acquisitions have been done to my knowledge this year.
Quite a amazing job done by a experienced management.
Keep in mind HFGB is selling well below B.V. stated @$0.70 before 2nd qtr results.
Accounts receivable also decreased in the 2nd qtr in spite the huge revenue gains.
What more does a $0.55 stock need to do to gain recognition as a severely underpriced stock.
I am looking for eps of $0.225 in 2010 giving HFGB a p/e ratio of 2.5 in spite the excellant job done by management.
Sure some increase in shares outstanding should be expected at some point because management has visions of increasing the companies size 3 fold thru acquistions & increased manufactoring ability & cash flow while excellant can't pay for all that kind of growth.
HFGB..
Pappy on the way to $0.70 I was able to sell on a scale starting at $0.6588 38K and have bought half of that back .. I'm befuddled by the action in HFGB but it seems that one by one each Company From China is getting crushed.. WBKT started my markdowns and it appears that CBP has continued the same.. These were the good ones but when SOKF failed to meet it's goals being long almost 30K hirt the most( which I have parred down to less than 10K)..
I have a theroy,, They go public thru a back door.. Add to assets for a couple of years and then stop adding and the EPS go flat either thru increased shares or the parts added just dont hold up.. There seems also always a discrepancy between shares and fully diluted shares..
Hopefully HFGB is different and thats all I can do as I still have over 60K in position..
KIK who I respect thinks I'm nuts for still making markets in them but like many I thought they were cheap.. The problem is that they are not as cheap as the gifts of stock in China that always seem to flog our markets.. These stocks sell a big discounts for two reasons.. No one believes any longer and the insider selling is horrendous in some issues.. I'll trade myself out of the ones that trade and stick the rest in my grandkid's college funds.. Theres hope but not in my lifetime.. CCME, UTA, which I have never owned and NEP are favorites that puzzled all.. I have found that once I leave my comfort zone I get far too opinionated and it causes losses.. Now unless the idea isn't mine will stay away and trade my way out of this wet bag of s--t.. That way I'll have no excuses for the lack of transperancy.. hank
Seems to me this SHOULD triple just to get to fair value.
If it were a US co., it would already be $3+. LOL
Does this stock deserve to triple?
I have a $1.40 pps target by yearend "if" the market god's are welling to let sound reason prevail.
At $1.40 hfgb would be valued @ 2x B.V. but only 7 x conservative eps guidance of $0.20 for 2010 up from $0.15 in 2009 when 25% fewer shares were outstanding.
Actually I expect eps to be close to $0.23 in 2010.
"What we might expect to occur in the 2nd half."
A reverse split to achieve listing requirements [since that is the companies stated objective] Before raising more funds to achieve growth at the next level as a full pharm. thru planned acquisitions & building.
Today's news from HFGB looks outstanding. Headed much higher I'd guess...near term triple? Longer term ten bagger easy imo.
GL
HFGB.. $0.68
I'm with you pappy,, I sold about 20K @ $0.68 + yesterday and am back on the bid to replace.. Still long a bunch.. hank
Take it back to $1.50 folks...these China micros are super bargains...we should see many dozens of triplers in this sector by Christmas. Ho Ho Ho.
Some high lites;
In spite having 20% more diluted shares EPS advanced to $0.06 vs $0.04 y/y on revenue of $6,698,952 or +116% y/y with margins improving from 32.9% to 37.7%.
Running 12 month EPS $0.22 which is the conservative guidance given for full year 2010.
Even after todays strong current pps gains the p/e ratio is still only 3 making this a very good time still to buy more.
HFGB.. $0.61 nice earnings..hank
HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC
AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
For the Three For the Three For the Six For the Six
Months Ended Months Ended Months Ended Months Ended
June 30, 2010 June 30, 2009 June 30, 2010 June 30, 2009
NET SALES $ 6,698,952 $ 3,091,525 $ 10,850,838 $ 4,417,420
COST OF SALES (4,231,888 ) (1,914,020 ) (6,761,042 ) (2,965,860 )
GROSS PROFIT 2,467,064 1,177,505 4,089,796 1,451,560
OPERATING EXPENSES
Selling and distribution expenses 41,600 34,571 60,392 86,929
General and administrative expenses 330,811 32,707 575,151 441,406
Depreciation and amortization 6,031 6,375 11,258 12,844
Total Operating Expenses 378,442 73,653 646,801 541,179
INCOME FROM CONTINUING OPERATIONS 2,088,622 1,103,852 3,442,995 910,381
OTHER INCOME (EXPENSE)
Interest income 1,521 1,128 3,032 1,360
Interest expense (280,512 ) (147,702 ) (588,294 ) (289,805 )
Other income 187,548 51,477 280,479 51,477
Total Expenses, net (91,443 ) (95,097 ) (304,783 ) (236,968 )
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 1,997,179 1,008,755 3,138,212 673,413
INCOME TAX EXPENSE (389,346 ) (139,574 ) (638,285 ) (184,571 )
NET INCOME FROM CONTINUING OPERATIONS 1,607,833 869,181 2,499,927 488,842
DISCONTINUED OPERATIONS
Loss from discontinued operations, net of income taxes - (8,574 ) - (16,961 )
Loss from disposal of discontinued operations - (34,446 ) - (34,446 )
NET LOSS FROM DISCONTINUED OPERATIONS - (43,020 ) - (51,407 )
NET INCOME 1,607,833 826,161 2,499,927 437,435
Less: net income attributable to non-controlling interests (75,531 ) (22,967 ) (103,736 ) (26,878 )
NET INCOME ATTRIBUTABLE TO HFGB COMMON STOCKHOLDERS 1,532,302 803,194 2,396,191 410,557
OTHER COMPREHENSIVE INCOME
Total other comprehensive income 76,453 1,319 79,022 16,251
Add (less): foreign currency translation (gain) loss attributable to non-controlling interests (2,623 ) 24 (2,712 ) (1,071 )
Foreign currency translation gain attributable to HFGB common stockholders 73,830 1,343 76,310 15,180
COMPREHENSIVE INCOME ATTRIBUTABLE TO HFGB COMMON STOCKHOLDERS $ 1,606,132 $ 804,537 $ 2,472,501 $ 425,737
Income per share – basic
Continuing operations $ 0.07 $ 0.04 $ 0.10 $ 0.02
Discontinued operations - - - -
Net income per share - basic $ 0.07 $ 0.04 $ 0.10 $ 0.02
Income per share - diluted
Continuing operations $ 0.06 $ 0.04 $ 0.10 $ 0.02
Discontinued operations - - - -
Net income per share - diluted $ 0.06 $ 0.04 $ 0.10 $ 0.02
Weighted average number of shares outstanding during the period - basic 23,665,035 18,466,169 23,371,423 18,466,169
Weighted average number of shares outstanding during the period - diluted 25,408,941 20,466,169 25,134,705 20,466,169
The accompanying notes are an integral part of these consolidated financial statements.
Although not the lowest price recently quoted, I am trying to accumulate at .63 or better. While the chinese micros have suffered I am hopeful that this one will eventually have the value relative to a solid earnings stream realized. At $ 1.00/share, that is a 50%+ gain which, IMO, is a reasonable goal.
Long. May have to wait longer than hoped. Crusader Rabbit
Spain has no money.
-----Original Message-----
From: Lou Restivo <lrestivo@biagiocru.com>
To: Shareholders
Sent: Thu, Jul 15, 2010 1:13 pm
Subject: RE: Are you the Block Buster Distributor that Hall of Fame Beverages was talking about?
This company is not a partner with hall of fame beverage and never was all I am doing is helping them develope the brand we are not distributors all I am doing is to help put the in a national dist . network .Thank you
Lou Restivo
Biagio Cru and Estate Wines, L.L.C.
Director of Importing
Tel: 516.299.4346 (x223)
Fax: 516.299.4348
Cell: 516.852.7375
ALRIGHT STEVE!
Thanks PAPPY.... great stuff as usual. And yes...I've got some of the dogs you've mentioned in my port...junky penny stocks...just hoping they recover some day.
I have used a formula for buying stocks during a downdraft for many years with great success but it doesn't seem to work on Chinese stocks.
I look for stocks that are growing revenue & earninmgs at a 30%+ clip & then wait for them to come down 30-50% off their recent highs.
Stocks that come down more than 50% usually means the fundamentals are no longer valid.
hfgb had a high of $1.40 a 50% retracement would be to $0.70 which is B.V. & with revenue & earnings still growing at a very healthy clip in a country that is leading the world in growth especially "pharm" growth hfgb has a very strong product line hard to duplicate by any would be rival.
The above formula worked because a stock that continues to grow revenue & earnings in spite a overall downtrend in stocks could be expected to regain or pass its previous highs when stocks once more went into a uptrend.
Thus stocks down 30-50% could be expected to increase in pps 50-100% or more in order to regain the previous highs.
HFGB @ $1.40 had a p/e ratio around 10 & even though the pps dropped more than 50% revenue & earnings continue to grow.
If revenue & earnings come in as projected by management & I have no reason to doubt them since they have been very conservative & beat their projections in the past.
Then a p/e ratio based on 2010 eps would give hfgb a target pps of about $2.20-$2.40 or about 4x the current pps.
Just retracing to its previous high of $1.40 would be a very good return from the current pps.
hfgb has analyst coverage that seems to have researched hfgb & its products very well & given some very consevative revenue & earnings numbers that hfgb beat in 2009 & is on its way to beating again this year.
I have a large position established in hfgb & believe in a basket approach,however if 2nd qtr numbers beat last years numbers like they did in the 1st qtr I will continue to buy more until hfgb is valued by the market at a more reasonable value,,,todays pps of $0.55 is about a 2.5 p/e ratio of current eps of $0.20 making it very undervalued even for a Chinese stock.
I agree...but I'm already in for enough freebies on CKGT...been in since .45ish...and had been swing trading my freebies...back to full position...happy with what I plan to hold for a few years!
I'm watching for these US listed china plays to become darlings and get into a long term bubble mode! Then....I'll lighten way down on them and look for something oversold/undervalued elsewhere. I'm in over 100 US listed china plays now...close to 80% are "free" positions from many many swing trades.
Since you're talking cheap, try CKGT on today's pullback!
I bought HFGB today as well at $.55
At .55, I probably just bought a profitable fast growing, high margin co. at about 2x's 2010 earnings....
Wish I had some real cash now...china stocks are crazy low in general....
Added shares back at .55....headed back up I think. tdameritrade made me call the order in for a broker to place it. Those trades usually work out really well near term...not sure if there's some sort of correlation there.
Last time I sold some was at 1.20+...locked in a few freebie shares there...will look to get a larger long term stake next.
GL...chart is favorable for a swing trade...not rock bottom...but headed the right way. This one can move really fast...not very liquid...min. buying can run it 30%....
research report from Feb.
http://www.equitynet.net/pics/hfgb.pdf
Thanks Pappy. I'm going to scrounge around and find some cash for getting into this one. (Alas, i bought too much of CNAM and CCME at the low prices and don't have any dry powder left-- foolish me.)
The company has some quality products that are gaining market share.
They gave guidance somewhat better than the $0.21 you mentioned for 2010 & the company has been conservative & met or beat its guidance figures in the past.
I think there is a sellar probably someone who received cheap shares as payment in leu of cash for services & with no buyers the stock has been drifting down on light volume.
Currently the pps is well below stated B.V. of $0.70 with a current p/e ratio of 2.5 & just over 2 on a forward basis.
I haven't been buying much lately but have decided to increase my position here while average down my previous cost basis of $0.77.
Pappy, what's going on with HFGB? Is there an overhang worry about dilution of shares this year or is this just part of the indiscriminate selloff of sound, healthy China companies?
I'm thinking of buying some shares down here...
I noticed that Rottenbelly at Yahoo a few months ago reported guidance from HFGB of 0.21 per share for 2010.
Do you think that guidance still holds?
Thanks in advance...
--timothy
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
302
|
Created
|
10/17/05
|
Type
|
Free
|
Moderators |
Huifeng Bio-Pharmaceutical Technology Inc. (“Huifeng”) develops, produces and sells plant extracts, pharmaceuticals and pharmaceutical raw materials in mainland China and internationally. Founded in 2000, the Company holds the patent for a highly efficient process to extract rutin, one of a class of plant-derived chemicals called flavonoids, with anti-inflammatory, antioxidant and anticoagulant properties. Other flavonoid or flavonoid-derived Huifeng products include troxerutin, quercetin, ginkgo biloba, diosmin and l-rhamnose. Manufacturers buy these products for use as the building blocks of drugs, dietary supplements and as additives in functional foods and beverages.
The Company’s production facilities are ISO9001:2000 certified, a necessary international qualification for export sales. The Company also holds a Chinese Good Manufacturing Practices (GMP) certification that allows it to distribute domestically. Products manufactured under GMP conditions have higher quality, consistency and potency assurances. Huifeng’s participation in PRC government biopharmaceutical industry initiatives entitles them to obtain funding to research new products.
Huifeng’s production efficiency has allowed them to become the dominant Chinese producer and exporter of rutin and to develop related products. In 2005, internal R&D efforts produced efficient methods of extracting diosmin and L-rhamnose, and they have recently expanded production facilities to manufacture these new products.
Huifeng has a diverse customer base, including distributors and manufacturers in China, Japan, Hong Kong, Russia, India, Germany, and the U.S. In the first 9 months of 2006, approximately 60% of products were sold in China and 40% were exported.
Huifeng BioPharmaceutical Technology, Inc.
FL16B, Ruixin Bldg, No.25 Gaoxin Rd., Xi'an 710075 China.
Press Release Source: Huifeng Bio-Pharmaceutical Technology, Inc. On Monday August 23, 2010, 7:30 am EDT
XI'AN, China, Aug. 23 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board:HFGB.ob -News), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives today reiterated its financial results for its second quarter ended June 30, 2010.
Second Quarter 2010 Highlights
-- Revenue was $6,698,952, up 116.7% from the same quarter of 2009.
-- Gross profit was $2,467,064, up 109.5% from the second quarter of 2009
with gross margin of 36.8%, slightly decreased 1.3% from 38.1% for the
second quarter of 2009.
-- Net income was $1,532,302, an increase of $729,108 or 90.8% from the
second quarter 2009, and earnings per diluted share were $0.06 based on
25.4 million shares.
Second Quarter 2010 Results
Q2 2010 Q2 2009 CHANGE
Revenue $6.7 million $3.1 million +116.7%
Gross profit $2.5 million $1.2 million +109.5%
Net Income $1.5 million $0.8 million +90.8%
EPS (Diluted)* $0.06 $0.04 +50%
* Weighted average shares outstanding for Q2 2010 was 25,408,941 and for
Q2 2009 was 20,466,169."We are pleased to report record revenue and operating income in the quarter," Mr. Jing'an Wang, the Company's CEO, commented. "The large increase in profitability and top line growth can be attributed to the increase in our sales of pharmaceutical raw-material and pharmaceutical intermediates. We have seen increased orders of both Rutin series products and Diosmin. We plan on focusing to fulfill the entire demand in the coming year."
For the Three Months Ended June 30, 2010 and 2009
Revenues for the quarter ended June 30, 2010 were $6,698,952, an increase of $3,607,427, or 116.7%, from$3,091,525 for the same quarter in 2009. Our increase in sales revenues for the second quarter of 2010 was mainly due to the increase in our sales of pharmaceutical raw-material and pharmaceutical intermediates, which include our products of Rutin, Troxerutin, Quercetin and Diosmin. An analysis of our results in sales of our products is as follows:
For the quarter ended June 30
Product 2010 2009 Increase
Pharmaceutical intermediates $1,477,178 $765,929 $711,249
Pharmaceutical raw-material $4,712,016 $1,907,060 $2,804,956
Plant Extractive and others $509,758 $418,536 $91,222
TOTAL $6,698,952 $3,091,525 $3,607,427Our gross profit for the quarter ended June 30, 2010 was $2,467,064, an increase of $1,289,559, or 109.5%, from $1,177,505 for the same quarter in 2009 as a result of the increase in our products sold, mainly due to the sales increase of pharmaceutical raw-material.
Our gross margin as a percentage of revenues for 2010 slightly decreased 1.3% from 38.1% for the second quarter of 2009 to 36.8% in the same quarter in 2009, due to the slight increase in raw materials' price.
Net income for the quarter was $1,532,302, an increase of $729,108 or 90.8% from the second quarter of 2009, and earnings per diluted share were $0.06 based on 25.4 million shares.
For the Six Months Ended June 30, 2010 and 2009
Revenues for the six months ended June 30, 2010 were $10,850,838, an increase of $6,433,418, or 145.6%, from $4,417,420 for the same period in 2009. Our increase in revenues for the six months ended June 30, 2010was mainly due to the increase in our sales of pharmaceutical raw-material and pharmaceutical intermediates, which include our products of Rutin, L-Rhamnose, Quercetin and Diosmin. An analysis of our results in sales of our products is as follows:
Six months ended June 30
Increase/
Product 2010 2009 (Decrease)
Pharmaceutical intermediates $2,309,996 $897,790 $1,412,206
Pharmaceutical raw-material $7,889,535 $2,635,525 $5,254,010
Plant Extractive and others $651,307 $884,105 $(232,798)
TOTAL $10,850,838 $4,417,420 $6,433,418The gross profit for the six months ended June 30, 2010 was $4,089,796, an increase of $2,638,236 or 181% from $1,451,560 for the six months period ended June 30, 2009 as a result of the increase in our products sold.
Our gross margin as a percentage of revenues for the six months ended June 30, 2010 was slightly increased from 32.9% to 37.7%, which compared to the same period in 2009. The increase in gross margin was mainly due to the increase of the selling price of raw-materials during the quarter ended June 30, 2010.
Net income for the first half of fiscal year 2010 was $2,396,191, compared to $410,557 in the prior year's corresponding period, a 483.6% increase year over year, and earning per diluted shares were $0.10 based on 25.1 million shares.
Financial condition
As of June 20, 2010, the Company had $1,661,815 in cash, increased from $85,105 in the prior year's corresponding period; working capital was $13,321,969. Cash provided by operating activities were $1,643,604, compared to cash used in operating activities of $106,697 for the six months ended June 30, 2009, mainly due to a decrease in accounts receivable and inventories of $171,204 and $1,173,837, respectively, as well as an increase due to a stockholder of Xi'an Runfeng Investment Ltd. of $497,117 and increase in our net income from continuing operations.
The Company reaffirms its 2010 Guidance
For the calendar year ended December 31, 2010, Huifeng reaffirms its $20.0-$25.0 million in revenue and $4.5-$5.0 in net income guidance respectively. The Company expects revenue and earnings growth to continue through the second half of the year, as it enters its most profitable selling period during the third and fourth quarter harvest and squeezing seasons.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the Company's web site at: http://www.hfgb.cn/
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors disclosed in the Company's Annual Report on Form 10K for the year ended Dec. 31, 2009 and all of the Company's subsequent Quarterly Reports on Form 10Q, especially in the "Risk Factors" sections of these reports. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact:
Investor Relations:
Capital Group Communications, Inc.
Mr. Kevin Fickle
Tel: +1-925-330-8315
Email: Kevin@capitalgc.com
Company Contact:
Huifeng Bio-Pharmaceutical Technology, Inc.
Mr. Steven Tong, IR Director
Tel: +86-135-7211-8351
Email: Steven@xahuifeng.com
Kevin M Fickle
+415 644 5253 (Direct)
+415 332 7201 (Fax)
+925 330 8315 (Mobile)
kevin@nuwagroup.com
If you would like to speak to our sales staff, please email sales@xahuifeng.com or
fax our headquarters in Xi’an, China at 0086-29-88250444.
adam@adam-friedman.com or call 212-981-2529-x 18
Website: http://www.hfgb.cn
Company Officers:
Jing An Wang, CEO
Sanding Tao, CFO
Transfer Agent
Interwest Transfer Co., Inc.,
1981 E 4800 S.
Suite 100
Salt Lake City, UT 84117
Current Share Structure: updated as of March 19, 2008
Estimated Market Cap: $13,849,625.75
Outstanding Shares: 18,466,169
Number of Shareholders: 767
Approx Float: 2,100,000
Products:
Pharm.Raw Materials
Rutin Troxerutin Quercetin L-Rhamnone
Active Pharm.Ingredients
Silymarin Hesperidin Diosmin Matrine
Oxymatrine phytosterol Stigmasterol Pueraria
Reseveratrol Naringin Baicalin Berberine Hydrochlorrde.
10-Deacetyl Baccatin ? Paclitaxol
Plant Extracts
Epimedium Extract Ginkgo Biloba Leaf P.E Grape Seed.P.E Pueraria Lobata Extract
Magnolia P.E. Hawthorn Berry P.E. Bitter Melon P.E. Red Clover P.E.
chlorogenic acid Gynostema Extract Fructucs Aurantii P.E. Rhodiola Rosea P.E
Green Tea P.E.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |